Experimental drug KZR-616 tested for rare muscle disorders

NCT ID NCT04033926

Completed Disease control Sponsor: Kezar Life Sciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tested a drug called KZR-616 (zetomipzomib) in 25 adults with active polymyositis or dermatomyositis, two rare diseases that cause muscle inflammation and weakness. Participants received either the drug or a placebo for 16 weeks, then switched to the other treatment for another 16 weeks. The study measured changes in a muscle improvement score to see if the drug helps control symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KZR-616 (also called zetomipzomib)
What this could lead to: If it works, this could point toward a new treatment option for people with polymyositis or dermatomyositis, helping control muscle inflammation and weakness.
What could go wrong: This is a small Phase 2 trial with only 25 participants, so results may not apply to everyone. The drug may not show clear benefit over placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dermatomyositis muscle tissue disorder musculoskeletal system disorder myositis disease polymyositis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DERMATOMYOSITIS POLYMYOSITIS

Contacts and locations

Locations

KZR Research Site

Beverly Hills, California, 90211, United States
KZR Research Site

Orange, California, 92868, United States
KZR Research Site

Miami, Florida, 33136, United States
KZR Research Site

Atlanta, Georgia, 30322, United States
KZR Research Site

Kansas City, Kansas, 66160, United States
KZR Research Site

Baltimore, Maryland, 21224, United States
KZR Research Site

Ann Arbor, Michigan, 48109, United States
KZR Research Site

Great Neck, New York, 11021, United States
KZR Research Site

Duncansville, Pennsylvania, 16635, United States
KZR Research Site

Pittsburgh, Pennsylvania, 15213, United States
KZR Research Site

Austin, Texas, 78756, United States
KZR Research Site

Henrico, Virginia, 23233, United States
KZR Research Site

Prague, Czechia
KZR Research Site

Göttingen, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.